Company: ARWR
Filing Date: 2025-11-25
Form Type: 10-K
Source: 0000879407-25-000029
Chunk: 163

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-11-25
Form: 10-K
Item: Item 8
Chunk 163
---
2021 Incentive Plan)Registration Statement on Form S-8, as Exhibit 99.2February 28, 202410.10**Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)Registration Statement on Form S-8, as Exhibit 99.3December 22, 202110.11**Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)Annual Report on Form 10-K, as Exhibit 10.11November 29, 202310.12**Executive Incentive Plan, adopted December 12, 2006Annual Report on Form 10-K, as Exhibit 10.11December 14, 200610.13**Arrowhead Pharmaceuticals, Inc. Inducement PlanQuarterly Report on Form 10-Q, as Exhibit 10.1May 9, 202410.14**Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008Current Report on Form 8-K, as Exhibit 10.1June 13, 200810.15**Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009Annual Report on Form 10-K, as Exhibit 10.8December 22, 200910.16†Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October 29, 2009Annual Report on Form 10-K, as Exhibit 10.36December 20, 201110.17†Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011Annual Report on Form 10-K, as Exhibit 10.33December 20, 201110.18†License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.Quarterly Report on Form 10-Q, as Exhibit 10.1August 12, 2014

76

Incorporated by Reference HereinExhibitNumberDescriptionFormDate10.19†Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016Annual Report on Form 10-K, as Exhibit 10.19December 14, 201610